Opthea (OPT) Competitors $5.02 +0.03 (+0.60%) Closing price 02/21/2025 03:55 PM EasternExtended Trading$4.58 -0.44 (-8.86%) As of 02/21/2025 05:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends OPT vs. DNLI, ZLAB, XENE, RXRX, TWST, VCEL, MOR, MLTX, MRUS, and CPRXShould you be buying Opthea stock or one of its competitors? The main competitors of Opthea include Denali Therapeutics (DNLI), Zai Lab (ZLAB), Xenon Pharmaceuticals (XENE), Recursion Pharmaceuticals (RXRX), Twist Bioscience (TWST), Vericel (VCEL), MorphoSys (MOR), MoonLake Immunotherapeutics (MLTX), Merus (MRUS), and Catalyst Pharmaceuticals (CPRX). These companies are all part of the "pharmaceutical products" industry. Opthea vs. Denali Therapeutics Zai Lab Xenon Pharmaceuticals Recursion Pharmaceuticals Twist Bioscience Vericel MorphoSys MoonLake Immunotherapeutics Merus Catalyst Pharmaceuticals Opthea (NASDAQ:OPT) and Denali Therapeutics (NASDAQ:DNLI) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their community ranking, valuation, institutional ownership, earnings, media sentiment, risk, profitability, analyst recommendations and dividends. Is OPT or DNLI more profitable? Opthea's return on equity of 0.00% beat Denali Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets OptheaN/A N/A N/A Denali Therapeutics N/A -32.94%-30.04% Which has better earnings and valuation, OPT or DNLI? Denali Therapeutics has higher revenue and earnings than Opthea. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOpthea$124.67K6,197.42-$220.24MN/AN/ADenali Therapeutics$330.53M9.04-$145.22M-$2.76-7.52 Does the MarketBeat Community favor OPT or DNLI? Denali Therapeutics received 441 more outperform votes than Opthea when rated by MarketBeat users. Likewise, 68.20% of users gave Denali Therapeutics an outperform vote while only 54.55% of users gave Opthea an outperform vote. CompanyUnderperformOutperformOptheaOutperform Votes1854.55% Underperform Votes1545.45% Denali TherapeuticsOutperform Votes45968.20% Underperform Votes21431.80% Do institutionals & insiders hold more shares of OPT or DNLI? 56.0% of Opthea shares are owned by institutional investors. Comparatively, 92.9% of Denali Therapeutics shares are owned by institutional investors. 3.2% of Opthea shares are owned by insiders. Comparatively, 7.9% of Denali Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Do analysts prefer OPT or DNLI? Opthea currently has a consensus price target of $12.00, suggesting a potential upside of 139.04%. Denali Therapeutics has a consensus price target of $37.42, suggesting a potential upside of 80.29%. Given Opthea's stronger consensus rating and higher probable upside, equities analysts plainly believe Opthea is more favorable than Denali Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Opthea 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Denali Therapeutics 0 Sell rating(s) 2 Hold rating(s) 12 Buy rating(s) 1 Strong Buy rating(s) 2.93 Which has more volatility & risk, OPT or DNLI? Opthea has a beta of 1.08, indicating that its stock price is 8% more volatile than the S&P 500. Comparatively, Denali Therapeutics has a beta of 1.43, indicating that its stock price is 43% more volatile than the S&P 500. Does the media favor OPT or DNLI? In the previous week, Opthea had 1 more articles in the media than Denali Therapeutics. MarketBeat recorded 4 mentions for Opthea and 3 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 0.65 beat Opthea's score of 0.20 indicating that Denali Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Opthea 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Denali Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryDenali Therapeutics beats Opthea on 9 of the 15 factors compared between the two stocks. Get Opthea News Delivered to You Automatically Sign up to receive the latest news and ratings for OPT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OPT vs. The Competition Export to ExcelMetricOptheaBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$772.61M$3.13B$5.77B$8.99BDividend YieldN/A1.57%4.78%3.85%P/E RatioN/A30.1126.4618.82Price / Sales6,197.42386.80453.6978.73Price / CashN/A183.5344.0437.47Price / Book-8.963.567.634.64Net Income-$220.24M-$71.72M$3.18B$245.69M7 Day Performance-3.65%-2.46%-1.91%-2.66%1 Month Performance13.83%-0.25%-0.19%-2.15%1 Year Performance53.99%-12.31%16.70%12.90% Opthea Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OPTOpthea2.0678 of 5 stars$5.02+0.6%$12.00+139.0%+46.8%$772.61M$124,666.000.008Upcoming EarningsDNLIDenali Therapeutics4.4388 of 5 stars$20.88-6.2%$38.00+82.0%+25.6%$3.01B$330.53M-7.57430ZLABZai Lab2.5867 of 5 stars$27.43-0.4%$55.00+100.5%+69.7%$3.00B$355.75M-9.902,175Upcoming EarningsNews CoverageGap UpXENEXenon Pharmaceuticals2.7111 of 5 stars$39.25+0.1%$56.00+42.7%-18.6%$2.99B$9.43M-13.92210Options VolumeNews CoverageRXRXRecursion Pharmaceuticals1.5118 of 5 stars$7.65+2.1%$8.75+14.4%-25.0%$2.99B$44.58M-5.00400Gap UpTWSTTwist Bioscience4.606 of 5 stars$48.63-7.0%$53.80+10.6%+7.7%$2.90B$312.97M-14.39990Positive NewsVCELVericel2.942 of 5 stars$58.65+0.5%$63.14+7.7%+8.0%$2.89B$197.52M977.66300Positive NewsMORMorphoSys0.1256 of 5 stars$18.96flat$18.25-3.7%N/A$2.86B$238.28M-5.45730Positive NewsMLTXMoonLake Immunotherapeutics2.0827 of 5 stars$44.07-2.2%$84.29+91.3%-21.0%$2.82BN/A-34.162News CoverageMRUSMerus2.9244 of 5 stars$40.64-1.5%$86.08+111.8%+5.3%$2.78B$35.93M-10.2937CPRXCatalyst Pharmaceuticals4.865 of 5 stars$22.76-0.6%$32.25+41.7%+57.7%$2.71B$460.48M19.2980 Related Companies and Tools Related Companies DNLI Alternatives ZLAB Alternatives XENE Alternatives RXRX Alternatives TWST Alternatives VCEL Alternatives MOR Alternatives MLTX Alternatives MRUS Alternatives CPRX Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:OPT) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | Sponsored[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWhat is this southern state hiding?The financial press had a field day this week after President Donald Trump and Department of Government Effici...Stansberry Research | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Opthea Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Opthea With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OPT Stock Alerts